S Takahashi, M Colvin, J Toyosawa, M Ishida, T Kagawa, S Kuraoka, Y Aoyama, K Okamoto, I Sakakihara, K Izumikawa, K Yamamoto, S Tanaka, M Matsuura, S Ishikawa, M Wato, T Hasui, T Inaba, Journal of Crohn’s and Colitis, Volume 12, Issue supplement_1, February 2018

Cytapheresis therapy as an additional therapy to oral tacrolimus is effective in patients with severe ulcerative colitis.

)https://academic.oup.com/ecco-jcc/article/12/supplement_1/S328/4808317

Tomoyoshi Shibuya ¹, Keiichi Haga ¹, Masato Kamei ¹, Koki Okahara ¹, Shoko Ito ¹, Masahito Takahashi ¹, Osamu Nomura ¹, Takashi Murakami ¹, Masae Makino ¹, Tomohiro Kodani ¹, Dai Ishikawa ¹, Naoto Sakamoto ¹, Taro Osada ¹, Tatsuo Ogihara ¹, Sumio Watanabe ¹, Akihito Nagahara ¹ , Intest Res. 2018 Jul;16(3):484-488.

Our experience indicates that GMA, as a non-drug therapeutic intervention with a favorable safety profile, plus tacrolimus might be a relevant treatment option for patients with active IBD during pregnancy. A future study of a large cohort of pregnant patients should strengthen our findings.

https://pubmed.ncbi.nlm.nih.gov/30090048/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077305/pdf/ir-16-484.pdf